Literature DB >> 1795933

Oxytocics for the prevention of post-partum haemorrhages. A review.

P W Van Dongen1, J Van Roosmalen, C N De Boer, J Van Rooij.   

Abstract

Secale alkaloids, oxytocin and prostaglandins are used to prevent post-partum haemorrhage (post-partum haemorrhage defined as blood loss greater than or equal to 500 ml). Any oxytocic drug administered in the third stage of labour reduces the blood loss with approximately 40% and hence the incidence of post-partum haemorrhage from 10 to 6%. Therefore, routine active management of the third stage with an oxytocic drug is strongly advocated. Because of the fewest side-effects oxytocin is regarded as the best drug available at this moment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1795933     DOI: 10.1007/BF02015577

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  20 in total

1.  Preliminary report on maternal deaths in the Southern Highlands of Tanzania in 1983.

Authors:  T G Price
Journal:  J Obstet Gynaecol East Cent Africa       Date:  1984-09

2.  THE SUBSTANCE RESPONSIBLE FOR THE TRADITIONAL CLINICAL EFFECT OF ERGOT.

Authors:  H W Dudley; C Moir
Journal:  Br Med J       Date:  1935-03-16

Review 3.  Induction and augmentation of labor: basis and methods for current practice.

Authors:  B A Brindley; R J Sokol
Journal:  Obstet Gynecol Surv       Date:  1988-12       Impact factor: 2.347

4.  A prospective survey of the outcome of pregnancy in a rural area of the Gambia.

Authors:  A M Greenwood; B M Greenwood; A K Bradley; K Williams; F C Shenton; S Tulloch; P Byass; F S Oldfield
Journal:  Bull World Health Organ       Date:  1987       Impact factor: 9.408

5.  Classic pages in obstetrics and gynecology. A new active principle in ergot and its effects on uterine motility. A preliminary report.

Authors:  M E Davis; F L Adair; G Rogers; M S Kharasch; R R Legault
Journal:  Am J Obstet Gynecol       Date:  1974-09-15       Impact factor: 8.661

6.  Postpartum haemorrhage--a continuing problem.

Authors:  L Gilbert; W Porter; V A Brown
Journal:  Br J Obstet Gynaecol       Date:  1987-01

7.  Potency of ergometrine in tropical countries.

Authors:  G J Walker; H V Hogerzeil
Journal:  Lancet       Date:  1988-08-13       Impact factor: 79.321

8.  Uterine motility after post-partum application of sulprostone and other oxytocics.

Authors:  K Baumgarten; J Schmidt; A Horvat; M Neumann; R Cerwenka; W Gruber; H D Gödicke; W Grünberger; J Spona
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1983-11       Impact factor: 2.435

9.  A randomized comparison of oxytocin, sulprostone and placebo in the management of the third stage of labour.

Authors:  R P Poeschmann; W H Doesburg; T K Eskes
Journal:  Br J Obstet Gynaecol       Date:  1991-06

10.  The Bristol third stage trial: active versus physiological management of third stage of labour.

Authors:  W J Prendiville; J E Harding; D R Elbourne; G M Stirrat
Journal:  BMJ       Date:  1988-11-19
View more
  3 in total

Review 1.  Physicochemical and formulation developability assessment for therapeutic peptide delivery--a primer.

Authors:  Annette Bak; Dennis Leung; Stephanie E Barrett; Seth Forster; Ellen C Minnihan; Andrew W Leithead; James Cunningham; Nathalie Toussaint; Louis S Crocker
Journal:  AAPS J       Date:  2014-11-15       Impact factor: 4.009

Review 2.  Ergot alkaloids. Current status and review of clinical pharmacology and therapeutic use compared with other oxytocics in obstetrics and gynaecology.

Authors:  A N de Groot; P W van Dongen; T B Vree; Y A Hekster; J van Roosmalen
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

3.  Towards heat-stable oxytocin formulations: analysis of degradation kinetics and identification of degradation products.

Authors:  Andrea Hawe; Robert Poole; Stefan Romeijn; Piotr Kasper; Rob van der Heijden; Wim Jiskoot
Journal:  Pharm Res       Date:  2009-04-03       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.